Caspofungin

Evidence Level: L5

Predicted Indications: 1

Caspofungin

Pharmacist Assessment Report

Caspofungin: From Esophageal Candidiasis and Candidemia to Gastrin Secretion Abnormality

One-Sentence Summary

Caspofungin is an echinocandin antifungal originally used to treat esophageal candidiasis and candidemia. The TxGNN model predicts it may be effective for gastrin secretion abnormality, but 0 clinical trials and 0 publications support this prediction, so it is a computational signal only.

Quick Overview

Item	Content
Original Indication	Esophageal candidiasis, candidemia
Predicted New Indication	Gastrin secretion abnormality
TxGNN Prediction Score	0.9944
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 5 of 6; cancelled: 1)
Number of DINs	6 (marketed: 5)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Caspofungin is known to inhibit beta-(1,3)-D-glucan synthase, an enzyme that fungi need to build their cell walls. This explains its efficacy against Candida infections.

The relationship between the original and new indications is weak. Gastrin is a hormone regulating gastric acid secretion, and humans have no beta-(1,3)-D-glucan synthase pathway. The review of the data found no known mechanism linking caspofungin to gastrin regulation.

The high TxGNN score (0.9944) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It should be treated as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

The five main ones are shown below.

DIN	Product Name
02244265	CANCIDAS
02244266	CANCIDAS
02460947	CASPOFUNGIN FOR INJECTION
02460955	CASPOFUNGIN FOR INJECTION
02486997	CASPOFUNGIN FOR INJECTION

Safety Considerations

Contraindications flagged in the knowledge graph (these come from drug-disease relationship data, not from label text): liver disease, gallbladder disease, potassium deficiency disease.
Drug Interactions: 81 interactions were identified.
- Major: dexamethasone
- Moderate: naltrexone
- Unclassified severity: many others, including amphotericin B, vancomycin, simvastatin, the proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), and several corticosteroids (prednisone, prednisolone, hydrocortisone)

Please refer to the package insert for complete warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or literature and no plausible mechanism, so it is a model output alone (L5). The product is well established in Canada for its antifungal uses, but that does not support this new indication.

Among the other predictions from the same analysis, neonatal candidiasis is much better supported. It has two Phase 2 neonatal trials (NCT00330395 and NCT01945281), a pediatric echinocandin meta-analysis, and a strong mechanistic fit. It would be a more productive candidate to pursue, although it sits close to the existing antifungal indication.

To proceed with gastrin secretion abnormality, the following is needed:

A plausible biological hypothesis linking caspofungin to gastrin regulation
Preclinical or mechanistic studies, as no human data exist
Complete safety data from the Canadian package insert, including warnings and contraindications
Mechanism of action data entered into the dataset
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.